# Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome

> **NCT00272844** · PHASE1,PHASE2 · COMPLETED · sponsor: **Boston Children's Hospital** · enrollment: 23 (actual)

## Conditions studied

- Smith-Lemli-Opitz Syndrome

## Interventions

- **DRUG:** crystalline cholesterol oil-based suspension

## Key facts

- **NCT ID:** NCT00272844
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-01
- **Primary completion:** 2011-06
- **Final completion:** 2011-07
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272844, "Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00272844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*